Compare IMPPP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPPP | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | Greece | United States |
| Employees | 49 | 34 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | IMPPP | SCLXW |
|---|---|---|
| Price | $25.73 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 741.0 | ★ 4.9K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $24.00 | $0.05 |
| 52 Week High | $27.78 | $0.64 |
| Indicator | IMPPP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 49.28 |
| Support Level | $25.58 | $0.11 |
| Resistance Level | $25.93 | $0.18 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 41.82 | 81.47 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.